Prosonix is the world leader in use of ultrasonic pharmaceutical particle engineering technologies for the manufacture of high value pharmaceutical powders and Making Better Medicines. Our pipeline addresses the fast-growing market sectors of asthma, COPD and other respiratory disorders, as well as niche opportunities in orally and parentally delivered products. Prosonix proprietary technologies can be used for API manufacture at any scale.
Prosonitron™, DISCUS®, UMAX®, SAX™ and PRT based process technologies are proprietary “Solution-to-Particle” methods for controlling crystal size, shape and polymorph for APIs, aimed at Making Better Medicines. Technologies offer dose-to-dose uniformity, formulation consistency, stability and 200% performance increase of inhaled APIs compared to micronized. Combination particles of multiple APIs can be manufactured.
Power ultrasound facilitates controlled and reproducible crystal nucleation which is fundamental in controlling crystallization. Sonocrystallization delivers controlled nucleation and superior control of particle size, morphology, polymorphism, crystallinity and purity, and in doing so helps eliminate the need for troublesome external seeding and micronization for inhaled medicines.
Multipurpose laboratory equipment for sonocrystallization & sonochemistry are now available. These highly effective and flexible research tools facilitate 100ml – 100L operational capability in batch or continuous operation and can be integrated with automated laboratory reactors. The unique designs allow seamless transition and scale up to Prosonitron™ technology for commercial scale operation.
Prosonix provide cGMP & ATEX sonocrystallization Prosonitron™ ultrasonic process and reactor technology. They are aligned with emergent FDA “QbD” and “Design for Intent” philosophy. Our proprietary systems are of modular design for optimum flexibility and are an easy retro-fit to existing equipment. They are proven across scale in API production and can be seen as sustainable green technology.
|
||||
|
<< Start < Prev 1 2 Next > End >> |
||||
| Page 2 of 2 |
Click here to visit the Prosonix Blog where Prosonix experts will post their thoughts on a regular basis. You can also submit your own content here and it will appear automatically in the blog following editor review.
| In just a short space of time since its launch Prosonix has successfully scaled up of the UMAX® particle engineering technology. The scale-up has now been carried out on several APIs in cGMP facilities and importantly demonstrates a seamless transition from laboratory to commercial scale batches, with no loss of formulation performance, independent of delivery platform or device. |